Drug
Dexanabinol
Dexanabinol is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (75.0%)
Phase 31 (25.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
Dexanabinol in Patients With Brain Cancer
NCT01654497
completedphase_1
A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
NCT01489826
unknownphase_1
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
NCT02423239
completedphase_3
Dexanabinol in Severe Traumatic Brain Injury
NCT00129857
Clinical Trials (4)
Showing 4 of 4 trials
NCT01654497Phase 1
Dexanabinol in Patients With Brain Cancer
NCT01489826Phase 1
A Phase 1 Study of Dexanabinol in Patients With Advanced Solid Tumours
NCT02423239Phase 1
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
NCT00129857Phase 3
Dexanabinol in Severe Traumatic Brain Injury
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4